Resolution of Marked Bradycardia Following Angioplasty

Khudheeja A Ahmed1, Juwayria Ahmed1, Mohammed Habeeb Ahmed2

  • 1Department of Research, Kaaj Healthcare, San Jose, USA.

Cureus
|January 12, 2024
PubMed

Insights

Bradycardia symptoms resolved after coronary angioplasty, suggesting coronary artery disease (CAD) may cause bradycardia. This highlights the need to evaluate for CAD before pacemaker implantation in bradycardic patients.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Internal Medicine

Background:

  • Bradycardia management typically involves conservative measures or pacemaker implantation.
  • Coexistence of bradycardia and coronary artery disease (CAD) presents complex clinical challenges.
  • Conventional treatment protocols may not always address underlying causes of bradycardia in CAD patients.

Observation:

  • This case report details an unusual instance where bradycardia and associated symptoms resolved post-coronary angioplasty.
  • The patient's bradycardia was linked to underlying coronary artery disease.
  • Resolution of bradycardia occurred without direct intervention for the arrhythmia itself.

Findings:

  • Coronary angioplasty led to the complete resolution of bradycardia in this patient.
  • This suggests a potential causal link between significant coronary artery disease and bradycardia.
  • The findings challenge the assumption that bradycardia always necessitates pacemaker implantation.

Implications:

  • Comprehensive evaluation for underlying coronary artery disease is crucial in patients with bradycardia before pacemaker implantation.
  • Considering CAD as a potential cause for bradycardia may prevent unnecessary pacemaker procedures.
  • This case advocates for a more individualized and integrated approach to managing patients with concurrent bradycardia and CAD.

Related Concept Videos

Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
544
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
593
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432